Patents Represented by Attorney, Agent or Law Firm Robert T. Ronau
-
Patent number: 8097621Abstract: This invention relates to compounds of formula (I)Type: GrantFiled: June 10, 2009Date of Patent: January 17, 2012Assignee: Pfizer Inc.Inventors: Andrew Simon Bell, David Graham Brown, Kevin Dack, David Nathan Abraham Fox, Ian Roger Marsh, Andrew Ian Morrell, Michael John Palmer, Carol Ann Winslow
-
Patent number: 8097733Abstract: The invention relates to compounds of formula (I) processes for their preparation, their use as 5-lipoxygenase inhibitors and pharmaceutical compositions containing the same.Type: GrantFiled: November 24, 2008Date of Patent: January 17, 2012Assignee: Pfizer Inc.Inventors: Edgardo Alvira, Matthew J. Graneto, Margaret Lanahan Grapperhaus, Kaliappan Iyanar, Todd Michael Maddux, Matthew William Mahoney, Mark Alan Massa, Kirby Ray Sample, Michelle Ann Schmidt, Ronald Edward Seidel, Jon Gordon Selbo, Michael Brent Tollefson, Richard Alan Vonder Embse, Grace Mary Wagner, Scott Santford Woodard
-
Patent number: 7183293Abstract: This application is directed to compounds of the formula wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W1 and W2 are independently —O— or —S(?O)t—, where t is 0, 1, or 2; Y is ?C(R1a)—, where R1a is a member selected from the group consisting of H; F; Cl; CN; NO2; —(C1–C4)alkyl; —(C2–C4)alkynyl; fluorinated-(C1–C3)alkyl; fluorinated-(C1–C3)alkoxy; —OR16; and —C(?O)NR22aR22b; R22a and R22b are defined as set forth in the specification; —RA and RB are each a member independently selected from the group consisting of H; F; CF3; —(C1–C4)alkyl; —(C3–C7)cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R10, which is defined as set forth in the specification; R16 and R17 are defined as set forth in the specification; —RC and RD have the same meaning as defined above for RA and RB except that one of them must be —H, and they are selected independently of each other and of RA and RB; R1 and R2 are each a membType: GrantFiled: August 13, 2004Date of Patent: February 27, 2007Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Anthony Marfat, Robert J. Chambers, Thomas V. Magee
-
Patent number: 7153870Abstract: This invention relates to nicotinamide derivatives of general formula (I): in which R1, R2 and R3 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.Type: GrantFiled: July 20, 2004Date of Patent: December 26, 2006Assignee: Pfizer Inc.Inventor: John Paul Mathias
-
Patent number: 6828333Abstract: This application is directed to compounds of the formula wherein j is 1; k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W1 and W2 are independently —O— or —S(═O)t—, where t is 0, 1, or 2; Y is ═C(R1a)—, where R1a is a member selected from the group consisting of H; F; Cl; CN; NO2; —(C1-C4) alkyl; —(C2-C4) alkynyl; fluorinated-(C1-C3) alkyl; fluorinated-(C1-C3) alkoxy; —OR16; and —C(═O)NR22aR22b; R22a and R22b are defined as set forth in the specification; —RA and RB are each a member independently selected from the group consisting of H; F; CF3; —(C1-C4) alkyl; —(C3-C7) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R10, which is defined as set forth in the specification; R16 and R17 are defined as set forth in the specification; —RC and RD have the same meaning as defined above for RA and RB except that oneType: GrantFiled: January 31, 2002Date of Patent: December 7, 2004Assignee: Pfizer Inc.Inventors: Anthony Marfat, Robert J. Chambers, Thomas V. Magee
-
Patent number: 6828315Abstract: The present invention relates to triazolo[4,3-a]quinazoline-5-ones and 5-thiones of Formula I and Formula II, whereby I and II are position isomers of group R on nitrogen 3 or 4. Optionally, the invention also relates to the racemic forms, isomers and pharmaceutically acceptable salts thereof. The invention further relates to a method for the production thereof and to compositions containing said derivatives.Type: GrantFiled: October 25, 2001Date of Patent: December 7, 2004Assignee: Warner-Lambert LLCInventors: Bernard Gaudilliere, Remi Lavalette, Charles Andrianjara, Francine Breuzard
-
Patent number: 6821964Abstract: Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein.Type: GrantFiled: March 6, 2002Date of Patent: November 23, 2004Assignee: Pfizer IncInventors: Roberto Colon-Cruz, Mary T. Didiuk, Erin M. Duffy, Ravi Garigipati, Wan F. Lau, Wayne S. McDonald
-
Patent number: 6787554Abstract: The invention relates to triazolo[4,3-a]pyrido[2,3-d]pyrimidine-5-one derivatives, their regioisomers, their salts and their solvates if they exist, their preparation, compositions containing them and their use. These derivatives possess properties inhibiting PDE4 and/or the release of TNF&agr;, and may therefore be used for the treatment or prevention of numerous conditions by virtue of the inhibition of the PDE4 enzyme and the resulting increase in the cAMP level.Type: GrantFiled: November 22, 2002Date of Patent: September 7, 2004Assignee: Warner-Lambert LLCInventor: Bernard Gaudillière
-
Patent number: 6756392Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions as well as for wounds healing.Type: GrantFiled: February 6, 2003Date of Patent: June 29, 2004Assignee: Pfizer IncInventor: Thomas V. Magee
-
Patent number: 6753322Abstract: The present invention relates to compounds of the formula: and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.Type: GrantFiled: June 5, 2001Date of Patent: June 22, 2004Assignee: Pfizer IncInventors: Simon John Mantell, Peter Thomas Stephenson
-
Patent number: 6753340Abstract: A compound selected from those of formula (I): wherein R1a, R1b, R2, R3, are as defined in the description, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of phosphosdiesterase-7 (PDE-7).Type: GrantFiled: March 27, 2003Date of Patent: June 22, 2004Assignee: Warner-Lambert Company LLCInventors: Fabrice Vergne, Patrick Bernardelli, Edwige Lorthiois, Pierre Ducrot
-
Patent number: 6747035Abstract: The invention relates to compounds of formula (I), in which R1, R2 and R3 are as defined in the description, their use as medicaments, the process for their preparation and their use for the treatment of pathologies in which therapy by a PDE4 inhibitor is relevant.Type: GrantFiled: August 2, 2002Date of Patent: June 8, 2004Assignee: Warner-Lambert LLCInventors: Bernard Guadillière, Remi Lavalette
-
Patent number: 6740655Abstract: This invention is directed to compounds of the formula: wherein j is 0 or 1; k is 0 or 1; m is 0 or 1; n is 0 or 1; W is —O—; —S(═O)t—, where t is 0, 1, or 2; or —N(R3)—; where R3 is —H, —(C1-C3) alkyl, —OR12, phenyl, or benzyl; RC and RD have the same meaning as RA and RB, except that at least one of RC and RD must be —H; and the other variables are defined as set forth in the specification. The invention is also directed to pharmaceutical compositions comprising the above compounds and to methods of treating a subject suffering from a disease, disorder or condition mediated by the PDE4 isozyme, the method comprising administering a therapeutically effective amount of a compound as described above.Type: GrantFiled: July 24, 2002Date of Patent: May 25, 2004Assignee: Pfizer IncInventors: Thomas Victor Magee, Anthony Marfat, Robert James Chambers
-
Patent number: 6716978Abstract: This application is directed to therapeutically active compositions of matter are useful for treating or preventing inflammatory bowel disease and conditions including joint inflammation, Crohn's disease and inflammatory bowel disease; respiratory diseases such as chronic obstructive pulmonary disease (COPD) including asthma, chronic bronchitis, and pulmonary emphysema; infectious diseases including endotoxic shock and toxic shock syndrome; immune diseases including systemic lupus erythematosis and psoriasis; and other diseases including bone resorption diseases and reperfusion injury; wherein said composition of matter comprises a compound which is an inhibitor of phosphodiesterase isozyme 4 (PDE4) and wherein an indazole is one essential component of said compound's overall chemical structure, and wherein said indazole constitutes a bioisosteric replacement of a catechol component or functional derivative thereof in a known compound having the same said therapeutic activity and the same remainingType: GrantFiled: September 20, 1999Date of Patent: April 6, 2004Assignee: Pfizer IncInventor: Anthony Marfat
-
Patent number: 6710040Abstract: The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inType: GrantFiled: June 3, 2003Date of Patent: March 23, 2004Assignee: Pfizer Inc.Inventors: Bernard Hulin, Janice C. Parker
-
Patent number: 6689881Abstract: Method for the preparation of enantiomerically pure diazepino-indolone of formula which comprises the intramolecular cyclization of a product of formula where A, B, X1, X2, Z, Z1, Z2 and R are as defined in the description, in the presence of a weak Lewis acid catalyst.Type: GrantFiled: April 3, 2002Date of Patent: February 10, 2004Assignee: Warner-Lambert LLCInventor: Patrick Bernardelli
-
Patent number: 6668527Abstract: There is disclosed a genus of non-peptidyl compounds, wherein said compounds are VLA-4 inhibitors useful in treating inflammatory, autoimmune, and respiratory diseases, and wherein said compounds comprise a compound of Formula (1.0.Type: GrantFiled: June 12, 2002Date of Patent: December 30, 2003Assignee: Pfizer Inc.Inventors: Allen J. Duplantier, Louis S. Chupak, Anthony J. Milici, Wan F. Lau
-
Patent number: 6667331Abstract: There is disclosed a genus of non-peptidyl compounds, wherein said compounds are VLA-4 inhibitors useful in treating inflammatory, autoimmune, and respiratory diseases, and wherein said compounds comprise a compound of Formula (1.0.Type: GrantFiled: June 12, 2002Date of Patent: December 23, 2003Assignee: Pfizer IncInventors: Allen J. Duplantier, Louis S. Chupak, Anthony J. Milici, Wan F. Lau
-
Patent number: 6660740Abstract: This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2 and R3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith.Type: GrantFiled: March 10, 2003Date of Patent: December 9, 2003Assignee: Pfizer IncInventors: Margaret Y. Chu-Moyer, Jerry A. Murry, Banavara L. Mylari, William J. Zembrowski
-
Patent number: 6649633Abstract: This application is directed to compounds useful as inhibitors at PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis and chronic obstructuive pulmonary disease, of the formula: where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, or 2; n is 1 or 2; W1 is —O—; or —S(═O)t—, where t is 0, 1, or 2; Y is —C(R1a); Q1 is phenyl or substituted phenyl; Q2 is biphenyl or substituted biphenyl; and the remaining variables are defined as set forth in the specification. This application is also directed to pharmaceutical compositions comprising those compounds and to methods of treating diseases regulated by the activation and degranulation of eosinophils, in particular asthma, chronic bronchitis and chronic obstructive pulmonary disease.Type: GrantFiled: January 31, 2002Date of Patent: November 18, 2003Assignee: Pfizer IncInventors: Robert J. Chambers, Anthony Marfat, Thomas V. Magee